bristol myers stock: BMY overview and data

Bristol‑Myers Squibb Company (BMY) — Stock

As of January 2026, this article summarizes key public-market information about bristol myers stock (ticker: BMY) and explains how traders and investors typically track and evaluate the common equity of Bristol‑Myers Squibb Company. You will find listing and identification details, market data and trading characteristics, historical performance highlights, core financial metrics, dividend and capital-allocation information, major corporate events that move the share price (M&A, clinical readouts, litigation and patent events), ownership patterns, analyst coverage and practical guidance for tracking or trading BMY — with neutral, sourced facts and Bitget-focused trading recommendations.

Note: bristol myers stock quotations and derived metrics change in real time. The snapshot data in this article are labeled with sources and dates; always verify live quotes via your brokerage or the company investor relations page.

Company overview

Bristol‑Myers Squibb is a large, global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases across oncology, hematology, immunology, cardiovascular disease and other therapeutic areas. Corporate fundamentals such as R&D pipeline strength, product mix, patent lifecycles and regulatory approvals matter to equity investors because they drive revenue visibility, earnings power and long-term cash flows.

For bristol myers stock holders, the company’s pipeline outcomes, major product sales (including post-acquisition integration of prior transactions) and regulatory or legal developments are commonly the primary drivers of volatility. Institutional ownership and large-scale collaborations with biotech partners also shape longer-term expectations.

Stock identification and listing

Ticker and exchange

• Trading symbol: BMY
• Primary exchange: New York Stock Exchange (NYSE)
• Typical US-listed trading hours: 09:30–16:00 ET (regular session), with pre-market and after-hours sessions available through many brokerages.

Market quotes for bristol myers stock are typically reported as Last Price, Bid/Ask, Day High/Low and 52‑week High/Low. Real-time access is provided by financial data providers and brokerages; delayed quotes may appear in news services.

Security type and share class

Bristol‑Myers Squibb common equity trades under the ticker BMY and represents the ordinary common shares of the company. In addition to the common stock, investors can access other Bristol‑Myers Squibb instruments such as corporate bonds or exchange-traded funds (ETFs) that include BMY as a holding. No separate preferred public share class for BMY is commonly traded on major US exchanges.

Market data and trading characteristics

Market capitalization and shares outstanding

Market capitalization (market cap) represents the market value of all outstanding common shares and equals share price multiplied by shares outstanding. Shares outstanding and market cap are market‑dependent and update continuously with the last traded price.

• As of January 2026, according to major market reports (Benzinga, NYSE snapshots and Yahoo Finance summaries), bristol myers stock last traded in the mid‑$50s per share (see snapshot data below) and the company’s market capitalization was on the order of hundreds of billions of dollars; precise market-cap figures should be verified at the time of inquiry through the company investor relations page or a market data provider.

Why this matters: market cap is used to classify scale (large-cap vs mid-cap) and to compare valuation multiples among peers.

Liquidity and trading volume

Liquidity describes how easily shares of bristol myers stock can be bought or sold without materially affecting the price. Common measures:

• Average daily trading volume: an indicator of liquidity and commonly reported by data providers.
• Intraday bid/ask spread: narrower spreads generally indicate higher liquidity and lower transaction costs.

As of January 2026, intraday NYSE and Nasdaq activity reports listed bristol myers stock among the more actively traded large-cap healthcare names on many sessions, with single-session volumes typically measured in the low millions of shares. For example, NYSE most-active lists from market reporting showed daily volumes for BMY in the range of ~1.9 million to ~2.3 million shares on certain trading days (Source: AP/Benzinga market summaries, Jan 2026). Liquidity for BMY is generally strong relative to small-cap biotech names, reducing execution risk for most institutional and retail orders.

Price ranges and volatility

Investors should monitor intraday ranges, 52‑week high/low and historical volatility when assessing risk.

• Intraday volatility can spike around company releases (earnings, trial updates, FDA decisions) or major macro events.
• As of January 2026, bristol myers stock intraday ranges reported in market lists showed day highs and lows in the mid‑$50s, while 52‑week ranges vary over time and should be confirmed with live data (Sources: NYSE/Benzinga snapshots).

Volatility considerations: biotech and pharmaceutical stocks often react sharply to binary events (trial readouts, regulatory announcements). For BMY, large diversified product revenues and an established commercial footprint typically moderate single-event swings relative to early-stage biotechs, but pipeline news can still drive meaningful moves.

Historical price performance

Recent performance trends

• As of January 2026, bristol myers stock was trading in the mid‑$50s per share. Market news feeds and exchange most-active lists recorded BMY trading near $54–55 on several sessions, with contemporaneous daily volumes of approximately 1.9–2.3 million shares (Source: AP market lists; Benzinga market data, Jan 2026).

• Short-term performance (1‑month, year‑to‑date) for bristol myers stock tends to reflect a mix of clinical/regulatory catalysts and broader market moves in healthcare and large-cap equities. Daily coverage from financial media often highlights BMY among NYSE active names on days with healthcare sector rotation.

Long‑term performance and major turning points

Key long-term price drivers for bristol myers stock include:

• Major acquisitions and divestitures. Large M&A transactions can reshape future revenue and cost synergies, affecting valuation multiples.
• Transformational product approvals or failures. FDA approvals for major oncology or immunology drugs often drive durable upside; trial failures can reduce near-term revenue prospects.
• Patent expirations and generic competition affecting established products.

Recent historical milestone: the company’s acquisition of Celgene in 2019 was a transformational event that materially changed the company’s revenue base and pipeline exposure. Subsequent integration, divestitures and portfolio prioritization have continued to influence investor expectations and bristol myers stock performance over multiple years.

Financial metrics and fundamentals

Key financials

Investors commonly track revenue, operating income, net income, adjusted earnings per share (EPS) and common valuation multiples such as Price/Earnings (P/E), Price/Sales (P/S) and enterprise value multiples.

• Revenues reflect product sales and royalties; net income reflects after-tax profitability; EPS is used in earnings-per-share comparisons.
• Valuation multiples for bristol myers stock change with earnings, growth expectations and sector sentiment. Large-cap pharma typically trades at sector-relevant P/E ranges relative to peers.

For up-to-date numeric financials (most recent fiscal-year revenue, trailing‑12‑month EPS, and multiples), consult company filings and major financial data providers (company investor relations, Yahoo Finance, Morningstar). Financial releases are the authoritative source for GAAP and adjusted metrics.

Earnings releases and guidance

Quarterly earnings releases and management guidance are primary short-term catalysts for bristol myers stock. Typical effects:

• Beats or raises in guidance: can support positive price reactions.
• Misses or downward guidance: often lead to declines and analyst revisions.

Clinical or regulatory updates can have outsized effects on forward guidance if they affect expected launch timing or future revenue streams.

Dividends and shareholder returns

Dividend policy and yield

Bristol‑Myers Squibb has a history of paying dividends to common shareholders. Dividend yield and payout frequency are important for income-oriented investors.

• Dividend yield = annual dividend per share divided by current share price; it changes with price movements and declared dividends.
• As of January 2026, market summaries and dividend tables in financial data providers reported BMY as a dividend-paying large-cap pharma stock. For the current dividend rate and yield, check the latest company dividend announcement or a market-data feed (Source: Bristol‑Myers Squibb investor relations; Yahoo Finance).

Dividend considerations: yield signals income return but should be assessed alongside payout ratio and the company’s free cash flow sustainability.

Share buybacks and capital allocation

Bristol‑Myers Squibb periodically engages in share repurchase programs to return capital and offset dilution. Capital allocation decisions—R&D investment, M&A, dividends and buybacks—affect long-term EPS and shareholder value.

• Any active repurchase program is disclosed in company filings and investor presentations.
• Large acquisitions (e.g., Celgene) and strategic collaborations influence near-term cash usage and long-term capital-allocation flexibility.

Major corporate events affecting the stock

Mergers, acquisitions, and asset sales

Large M&A deals materially affect bristol myers stock by changing revenue composition, pipeline exposure and debt levels.

• Example: historical acquisition of Celgene reshaped the company’s oncology portfolio. Post‑deal integration, synergies, and divestiture decisions were key valuation drivers.

Investors monitor announced transactions, break fees, expected synergies and financing to assess likely stock impacts.

Clinical trial results, regulatory approvals, and product launches

For bristol myers stock, biotech-specific triggers are crucial:

• Positive phase results or regulatory approvals for key programs can drive significant upward moves.
• Negative readouts, safety signals or delayed approvals can prompt sharp declines.

Regulatory milestones are often binary and can cause outsized intraday volatility relative to broad-market moves.

Litigation, patent expirations, and generic competition

Legal outcomes and patent cliffs are principal risks for pharmaceutical companies.

• Patent expirations may open the door to generic competition and reduced pricing power for legacy products.
• Significant litigation (e.g., patent disputes, product liability suits) may involve damages and affect future revenues.

Investors review regulatory exclusivity timelines, pending litigation notes in filings and market commentary to quantify potential revenue risks.

Ownership and major shareholders

Institutional ownership

Large-cap pharmaceutical stocks like bristol myers stock typically have high institutional ownership from mutual funds, pension funds and asset managers. High institutional ownership can support liquidity but may also concentrate voting influence.

• Common large shareholders include global asset managers and healthcare-focused funds. Detailed institutional ownership lists are available in regulatory filings and major data providers.

Insider holdings and transactions

Insider holdings (executive officers and board members) and periodic insider transactions are reported in public filings. Patterns of insider buying or selling are considered by some investors as signals, but such activity must be interpreted in the appropriate context and does not constitute investment advice.

Analyst coverage and market sentiment

Analyst ratings and price targets

Bristol‑Myers Squibb receives broad coverage from sell‑side research analysts. Analyst consensus ratings (Buy/Hold/Sell) and median price targets provide a view of professional expectations but may vary.

• Analysts incorporate pipeline prospects, earnings trends and competitive dynamics into their models.
• After major events (earnings, regulators, M&A), analysts frequently update ratings and targets.

Media and investor commentary

Financial news, investment platforms and social sentiment influence short-term flows. For example, Jan 2026 market reports highlighted BMY among NYSE most-active names on some sessions. Major coverage by Benzinga and AP included trade prints and activity snapshots (Source: Benzinga, AP, Jan 2026).

Neutrality reminder: media coverage reflects news and sentiment; it should not be interpreted as investment advice.

Risks and considerations for investors

Industry and company‑specific risks

Principal risks relevant to bristol myers stock include:

• Pipeline failures or safety issues in clinical trials.
• Regulatory setbacks or approval delays.
• Patent expirations and generic entry for established products.
• Competitive dynamics from other pharma companies and new therapeutic modalities.

Market and macro risks

Broad factors that affect bristol myers stock include interest-rate moves, currency fluctuations, healthcare policy or pricing reforms and general equity market risk. Large-cap pharma can act as a defensive sector in some macro regimes, but correlation with the broader market is still present.

Related securities and instruments

Options, ETFs, and bonds

• Options: BMY options are typically available on US options exchanges, providing tools for hedging or expressing directional views; liquidity in the options market varies by strike and expiration.
• ETFs: Many healthcare and large-cap equity ETFs include bristol myers stock as a component; ETF flows can influence short-term demand for the underlying shares.
• Bonds: Bristol‑Myers Squibb issues corporate debt that is an alternative exposure to company credit risk rather than equity performance.

International listings and ADRs

Bristol‑Myers Squibb primarily trades on the NYSE under BMY for US investors. Non‑US investors can access BMY via global brokerages that provide access to US markets or via internationally listed funds and ETFs that hold BMY.

How to track and trade BMY

Primary data sources

Reliable sources for tracking bristol myers stock include:

• Company investor relations (official filings, press releases and presentations) — authoritative for corporate disclosures.
• Major market-data providers and financial news outlets for quotes and volume snapshots (examples: Yahoo Finance, Morningstar, CNBC, MarketWatch, The Motley Fool). Financial media provided the market snapshots cited in this article (Source: Benzinga/AP market lists, Jan 2026).
• Brokerage platforms for live execution and order routing.

When selecting a trading venue, consider execution quality, fees and available order types. For users of Bitget services: Bitget offers multi-asset trading and a market interface for US equities where available; for custody and wallet needs, Bitget Wallet is recommended in platform materials.

Trading considerations and best practices

• Order types: Market orders execute immediately but may incur slippage in volatile moments; limit orders allow price control.
• Taxes and settlement: US equity trades settle on a T+2 basis; capital gains treatment depends on holding period and investor jurisdiction.
• Monitoring: Track earnings dates, FDA / regulatory calendars, major investigator-initiated trial readouts and corporate announcements. Use calendar feeds from reliable data vendors.

Operational tip: For non-US retail traders, verify availability of US equities trading and ensure adherence to local regulations and tax reporting.

See also

• Bristol‑Myers Squibb (company profile and investor relations)
• Pharmaceutical industry overview
• Stock market investing basics
• Comparable large-cap pharma tickers and peer comparisons

References

• As of January 2026, market activity snapshots and most-active lists published by AP and Benzinga included bristol myers stock among NYSE active names; reported intraday prices were in the mid‑$50s and single-day volumes around 1.9–2.3 million shares (Sources: Associated Press market lists; Benzinga market reports, Jan 2026).
• Company investor relations filings and press releases (refer to Bristol‑Myers Squibb investor relations for official financial statements and corporate announcements).
• Financial-data and quote services (Yahoo Finance, Morningstar, MarketWatch, CNBC, The Motley Fool) for up‑to‑date quotes and valuation metrics.
• News on strategic collaborations: As reported in January 2026, Benzinga noted collaboration activity between Bristol‑Myers Squibb and biotech partners; for example, Janux Therapeutics announced a collaboration and exclusive license agreement with Bristol Myers Squibb, including up to $50 million upfront and potential total payments reaching approximately $800 million, with Bristol‑Myers Squibb managing subsequent development and commercialization responsibilities (Source: Benzinga, Jan 2026).

External links (names only — use your platform to access)

• Bristol‑Myers Squibb — Investor Relations
• NYSE — BMY market page
• Yahoo Finance — BMY quote and fundamentals
• Morningstar — BMY analysis
• CNBC / MarketWatch / The Motley Fool — coverage and news

Appendix: Selected market snapshot (reported session examples)

• Example session A (reported in market lists): bristol myers stock — Last: $55.26, Day High: $55.49, Day Low: $54.36, Volume: 1,886,725 shares (Source: AP market lists, Jan 2026).
• Example session B (reported in NYSE most-active lists): bristol myers stock — Last: $54.31, Day High: $54.35, Day Low: $53.65, Volume: 2,239,861 shares (Source: NYSE activity list reproduced in market coverage, Jan 2026).

These session snapshots illustrate that intraday price and volume can vary from day to day; consult live feeds for current values.

Practical checklist for tracking bristol myers stock

• Verify live quote and market-cap on your brokerage or a real-time data provider.
• Review the most recent quarterly earnings release and investor presentation.
• Monitor upcoming regulatory milestones and clinical trial readout dates relevant to core pipeline assets.
• Check institutional-ownership filings and recent insider transaction disclosures for changes in major shareholders.
• Use limit orders in volatile periods and consider liquidity and bid/ask spreads when sizing trades.
• For custody and wallet needs, consider Bitget Wallet for secure token custody and Bitget platform features for multi-asset users (subject to your regional availability and regulatory compliance).

Editorial notes and data sourcing

• Reported market snapshots and volumes are drawn from AP and Benzinga market lists and reflect the sessions reproduced by those services in January 2026.
• Financial statement details, dividend declarations and official corporate disclosures should be sourced directly from Bristol‑Myers Squibb investor relations and SEC filings for audit‑grade accuracy.
• This article is neutral and informational. It does not provide investment advice, recommendations, or personalized financial guidance.

Further exploration: explore Bitget platform features for trade execution, watchlists and market data tools to follow bristol myers stock in real time and receive alerts on corporate events and news.